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Nicotinamide adenine dinucleotide (NAD) is a REDOX cofactor and metabolite essential for neuronal survival.
Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline. We assess the effects
of nicotinamide (a precursor to NAD) on retinal ganglion cells (the affected neuron in glaucoma) in normal
physiological conditions and across a range of glaucoma relevant insults including mitochondrial stress and axon
degenerative insults. We demonstrate retinal ganglion cell somal, axonal, and dendritic neuroprotection by
nicotinamide in rodent models which represent isolated ocular hypertensive, axon degenerative, and mito
chondrial degenerative insults. We performed metabolomics enriched for small molecular weight metabolites for
the retina, optic nerve, and superior colliculus which demonstrates that ocular hypertension induces widespread
metabolic disruption, including consistent changes to α-ketoglutaric acid, creatine/creatinine, homocysteine, and
glycerophosphocholine. This metabolic disruption is prevented by nicotinamide. Nicotinamide provides further
neuroprotective effects by increasing oxidative phosphorylation, buffering and preventing metabolic stress, and
increasing mitochondrial size and motility whilst simultaneously dampening action potential firing frequency.
These data support continued determination of the utility of long-term nicotinamide treatment as a neuro
protective therapy for human glaucoma.
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nicotinamide’s use in the clinic, and support the initiation of clinical
trials to determine the effect of nicotinamide on longer-term disease
progression.

1. Background
Glaucoma is one of the most common neurodegenerative diseases,
and the leading cause of irreversible blindness, affecting ~80 million
people worldwide [1]. Age, genetics, and elevated intraocular pressure
(IOP) are major risk factors, but to date, the only clinically available
therapies target the reduction of IOP. For the many patients which are
refractory to IOP lowering treatments, surgical interventions are
commonly used in order to limit the progressive neurodegeneration and
visual impairment [2]. No therapy currently targets the neuronal pop
ulation that degenerates in glaucoma. Ultimately, 42% of treated glau
coma patients progress to blindness in at least one eye [3]. With an
increasingly aged population, glaucoma will continue to be a significant
health and economic burden and thus neuroprotective strategies tar
geting the retina and optic nerve are of great therapeutic need.
Retinal ganglion cells, the output neuron of the retina whose axons
converge to form the optic nerve, display a progressive, compartmen
talized neurodegeneration leading to the characteristic visual dysfunc
tion seen in glaucoma. We have previously demonstrated mitochondrial
abnormalities occurring prior to neurodegeneration in glaucoma (in
glaucoma patients and animal models [4,5]). The latter study, utilizing
the DBA/2J mouse model of glaucoma, has identified that nicotinamide
adenine dinucleotide (NAD; an essential REDOX cofactor and metabo
lite) declines in the retina in an age-dependent manner and renders
retinal ganglion cells susceptible to IOP-related stress, driving glau
comatous neurodegeneration. The prevention of NAD decline by dietary
supplementation with nicotinamide (NAM; the amide form of vitamin
B3, an NAD precursor via the NAD-salvage pathway in neurons) or by
intravitreal viral gene-therapy overexpressing Nmnat1 (a terminal
enzyme for NAD production) was robustly protective against retinal
ganglion cell neurodegeneration and prevented a number of early gene
expression changes in DBA/2J retinal ganglion cells [5]. Glaucoma pa
tients have been demonstrated to have systemically low levels of NAM in
sera [6] which supports a hypothesis in which pathogenically low NAD
leads to glaucoma susceptibility. These findings have driven interest in
nicotinamide as a treatment for glaucoma, including the planning and
initiation of a number of clinical trials, e.g. NCT03797469 which is
ongoing and Hui et al. (2020) which is now completed [7]. In this trial,
as part of a multi-national collaborative team, we have demonstrated
significant visual recovery in glaucoma patients over a 6 month treat
ment period (cross-over design; step up 1.5 g/d to 3.0 g/d nicotinamide
[7]). Nicotinamide’s excellent long clinical history, combined with good
safety profile, tolerance at high doses, and affordability has facilitated
rapid translation into initial small scale clinical trials [8,9]. However,
translation to larger scale trials, the evaluation of earlier intervention
protocols, and/or longer-term clinical outcomes requires a deeper un
derstanding of the effects of nicotinamide on retinal ganglion cells under
both neurodegenerative conditions and normal physiological states.
This is of critical importance since disease progression is often hetero
geneous (i.e. a mix of healthy, degenerating, and dead cells) and if
prophylactic treatment is to be considered (which is ideal since visual
deficits present once the degenerative processes have already been
initiated [10]).
We bridge the gap between the bench and bedside by demonstrating
further evidence of neuroprotection through nicotinamide supplemen
tation across a number of glaucoma-related retinal ganglion cell tar
geted insults, using a number of retinal ganglion cell specific tools. We
identify early metabolic changes in the retina in a rat model of ocular
hypertensive glaucoma (elevated IOP), which are prevented by nico
tinamide supplementation. Importantly, chronic dietary nicotinamide
supplementation causes limited metabolic variation in non-diseased
visual system tissues supporting potential prophylactic treatments.
Nicotinamide administration also buffers retinal ganglion cell meta
bolism, increases oxidative phosphorylation, and positively alters
mitochondrial morphology and dynamics in retinal ganglion cells at
doses which are neuroprotective. These data help support

2. Materials and methods
2.1. Animal strain and husbandry
All breeding and experimental procedures were undertaken in
accordance with the Association for Research for Vision and Ophthal
mology Statement for the Use of Animals in Ophthalmic and Research.
Individual study protocols were approved by Stockholm’s Committee for
Ethical Animal Research (10389-2018). Animals were housed and fed in
a 12 h light/12 h dark cycle with food and water available ad libitum.
Adult, male Brown Norway rats (BN, aged 12–20 weeks, weighing
300–400 g, SCANBUR) were utilized for inducing ocular hypertension
(detailed below). C57BL/6J and MitoV (strain details and generation
detailed below) mouse strains were bred and utilized at 12–20 weeks of
age. For rats, Nicotinamide (NAM, PanReac AppliChem) was dissolved
in drinking water (200 mg/kg/d, based on average consumption).
Higher doses were achieved by combining treated drinking water and a
custom diet (3130 ppm NAM to achieve 400 mg/kg/d, or 9380 ppm
NAM to achieve 800 mg/kg/d based on a pre-determined g/d con
sumption of chow, base RM3 P diet, SDS). For mice, NAM was dissolved
in drinking water (500 mg/kg/d based on average consumption). Water
was protected from light and changed every 3–5 days and chow was
maintained as necessary; both were provided in sufficient quantity to be
available ad libitum.
2.2. Induction and monitoring of rat ocular hypertension
Rat ocular hypertension was induced using a paramagnetic bead
model as previously described [11]. Rats were anesthetized with an
intraperitoneal injection of ketamine (37.5 mg/kg) and medetomidine
hydrochloride (1.25 mg/kg). Microbeads (Dynabead Epoxy M − 450,
Thermo Fisher) were prepared in 1x Hank’s balanced salt solution (HBSS
-CaCl2 –MgCl2 -phenol red, Gibco) and 6–8 μl of bead solution was
injected into the anterior chamber. Beads were directed with a magnet
to block the iridocorneal angle. Rats received either bilateral injections
(OHT) or remained bilateral un-operated (naïve), normotensive controls
(NT). For rats pre-treated with NAM, NAM was given 1 week prior OHT
induction (at either 200, 400, or 800 mg/kg/d) and maintained
throughout the duration of the experiment. Intraocular pressure (IOP)
was measured using a rebound tonometer (Tonolab, Icare). Rats were
habituated to tonometry in the week prior to induction. Baseline IOP
was recorded the morning before surgery and every 2–4 days after
wards. Rats were awake and unrestrained for tonometry. IOP recordings
were always performed between 9 and 10am to avoid the effects of the
circadian rhythm on IOP.
2.3. OCT imaging
Optical coherence tomography (OCT) was performed at 14 days post
IOP in BN rats, prior to euthanasia (n = 9 eyes NT, 7 OHT, 8 OHT treated
with 200 mg/kg/d NAM (OHT-NAM)). Pupils were dilated with topical
Phenylephrine Hydrochloride (2.5% w/v) eye drops before anesthesia
was induced with an intraperitoneal injection of ketamine and mede
tomidine hydrochloride as above. OCT imaging was performed using a
Phoenix Micron IV (Phoenix) with image-guided OCT attachment. Bscans centered on the ONH were captured in the horizontal and vertical
plane. Image analysis was performed in MATLAB (MATrix LABoratory).
First the retinal pigment epithelium and internal limiting membrane
were delineated manually. In the presence of cupping, the cup depth was
measured automatically as the vertical distance between the cup base
and midpoint of the neuroretinal peaks. This measurement was used to
determine loss of neuroretinal rim.
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nerve head (~1000 μm eccentricity). Images were cropped to 150 μm2
and RBPMS + cells and DAPI nuclei counted using the cell counter
plugin for Fiji ([16]; only round nuclei were counted, thus excluding
vascular endothelium); counts were expressed as a density per 0.01
mm2, averaged across the 6 images. For measurement of nuclear
diameter, 30 nuclei (from RBPMS + cells; or as many surviving cells as
were able to be measured) per cropped image were measured using the
line tool, giving an average diameter; this was averaged across the 6
images to produce a final average diameter per retina. These analyses
were performed on rat retina (n = 10 eyes from NT, 10 eyes from OHT, 9
eyes from OHT-NAM [200 mg/kg/d], 12 eyes from OHT-NAM [400
mg/kg/d], 12 eyes from OHT-NAM [800 mg/kg/d]), C57BL/6J mouse
retina from retinal explants (n = 6 eyes for all groups: 0 days ex vivo
(DEV; control), 0.5 DEV, 1 DEV, 3 DEV, 5 DEV, 3 DEV + NAM [100 mM],
3 DEV + NAM [500 mM]), C57BL/6J mouse retina from intravitreal
rotenone injection (n = 8 eyes from DMSO control, 8 eyes from rotenone
injected, 8 eyes from rotenone + NAM [500 mg/kg/d]).

2.4. Retina axotomy explant model
A retinal axotomy model was established with modification form
previously described protocols [12,13]. Mice were euthanized by cer
vical dislocation and eyes immediately enucleated. Retinas were
dissected free in cold HBSS and flat mounted on cell culture inserts
(Millicell 0.4 μm pore; Merck) ganglion cell layer up. Retinas were
maintained in culture (37 ◦ C, 5% CO2) fed by Neurobasal-A media
supplemented with 2 mM L-glutamate (GlutaMAX), 2% B27, 1% N2, and
1% penicillin/streptomycin (all Gibco) in 6-well culture plates. Half the
media volume was changed after 2 days. For NAM treated retinas, NAM
was dissolved in the culture media to a concentration of 100 mM or 500
mM. Retinas were removed from culture for further processing after 12
h, 1 day, 3 days or 5 days ex vivo (DEV).
2.5. Intravitreal rotenone model
Rotenone toxicity induced degeneration was induced in the retina
following established protocols [14,15]. Mice were anesthetized with an
intraperitoneal injection of ketamine (37.5 mg/kg) and medetomidine
hydrochloride (1.25 mg/kg). Bilateral intravitreal injections were per
formed using a 33G tri-beveled needle on a 10 μl glass syringe (WPI).
One μl of a 10 mM rotenone (MP Biochemicals) solution dissolved in
DMSO (PanReac AppliChem) or DMSO only (vehicle only control) was
injected into the vitreous and the needle maintained in place for 30 s for
distribution. For NAM pre-treated retinas, NAM (500 mg/kg/d) was
administered in drinking water 1 week prior to rotenone injection. Mice
were euthanized 24 h after injection by cervical dislocation and eyes
immediately enucleated for further processing.

2.9. Analysis of RGC axonal degeneration
Axon integrity in the nerve fiber layer (NFL) of retina following
axotomy explant was assessed relative to control (n = 6 eyes for all
groups: 0 days ex vivo (DEV; control), 3 DEV, 3 DEV + NAM [100 mM], 3
DEV + NAM [500 mM]). Images of β-tubulin labelled axons adjacent to
the optic nerve head were acquired on a Zeiss Axioskop 2 plus epi
fluorescence microscope, cropped to 250 × 50 μm size and the size and
number of varicosities measured. Images were converted to 8 bit,
thresholded (200–255) and binarised. Varicosities were analyzed using
the ImageJ particle analyzer (Fiji; 1–10 μm size filter to remove single
pixel and long, thin axon segments [17]). The number of particles/mm2
and the average size of particles (μm2) were taken as varicosity density
and size.

2.6. Cryo-sectioning
Rats were heavily anesthetized by intraperitoneal injection of
pentobarbital (75 mg/kg) and euthanized by cervical dislocation. Mice
were euthanized by cervical dislocation. Eyes for cryo-sectioning were
enucleated and fixed by immersion in 4.7% PFA for 24 h. The tissue was
cryo-protected by immersion in 30% sucrose for 24 h before freezing in
optimal cutting temperature medium (Sakura) on dry ice. Blocks were
maintained at − 80 ◦ C until use. 20 μm cryo-sections were cut (anterior
to dorsal plane) using a cryostat (Cryostar NX70, Thermo Scientific) and
stored at − 20 ◦ C.

2.10. Analysis of RGC dendritic degeneration
Dendritic degeneration was assessed in axotomy explant retina
through DiOlistic labelling of individual RGC dendritic arbors (using a
Helios gene gun system, Biorad, as previously described [18]). Bullets
were prepared at a ratio of 2 mg DiI, 4 mg of DiO, and 80 mg Tungsten
(1.7 μm diameter) to 30.5 cm of Tezfel tubing (Biorad), by dissolving the
dyes in 400 μl of methylene chloride and applying over the tungsten to
air dry. The coted tungsten was collected and transferred into the tubing,
and distributed along the length of the tubing by vortexing. Individual
bullets were cut to 1.2 cm C57BL/6J mouse retinas were subject to
axotomy explant (n = 10 eyes for 0 days ex vivo (DEV; control), 12 eyes
for all 3 DEV groups: 3 DEV, 3 DEV + NAM [100 mM], 3 DEV + NAM
[500 mM]) and labelled ballistically. For 0 DEV, retinas were dissected
in HBSS and immediately labelled, for 3 DEV groups retinas were
removed from culture and labelled. For labelling, retinas were flat
mounted on to glass slides, all liquid was removed, a culture insert was
inverted over the retina to act as a filter to large particle clumps, and the
contents of a single bullet discharged at a gene gun pressure of 120 psi.
Tissue was transferred to a culture dish containing Neurobasal-A media
(supplemented as in the retina axotomy explant model above) and
maintained at 37 ◦ C, 5% CO2 for 30 min. Retinas were then fixed in 4%
PFA for 1 h, washed in 1 M PBS, nuclei labelled with Hoechst (Invi
trogen) for 15 min, washed again and mounted with FluorSave reagent
(Merck). After drying, coverslips were sealed. Images of individual RGC
dendritic arbors were acquired on a Leica SP8 confocal microscope
(Leica Systems; 20X magnification, 0.45 μm/pixel, 1 μm z-thickness).
Whole dendritic arbors were reconstructed using Imaris (version 9.3.1,
Bitplane) where individual RGC dendritic fields were manually selected
as areas of interest (used to calculate dendritic field areas) and dendrites
automatically traced using the filaments tool. Total dendritic length was
calculated and Sholl analysis performed (dendritic intersections per
binned distance from the soma center, 10 μm steps) and area under the

2.7. Immunofluorescent labelling
Immunofluorescent labelling followed a standard protocol for cryosections and flat mount retina with the following exceptions. Cryosections were air dried for 15 min and rehydrated in 1 M PBS for 5
min before following the protocol. Antibodies are detailed in Supple
mentary Table 1. For the standard protocol, tissue was isolated using a
hydrophobic barrier pen (VWR), permeabilized with 0.5% Triton X-100
(VWR) in 1 M PBS for 30 min, blocked in 5% bovine serum albumin
(Fisher Scientific) in 1 M PBS for 30 min, and primary antibody applied
and maintained overnight at 4 ◦ C. 5 × 5 min washes in 1 M PBS were
performed before applying secondary antibodies and maintaining at
room temperature for 2 h. Tissue was washed as before and DAPI nu
clear stain (1 μg/ml in 1 M PBS) was applied for 10 min. Tissue was then
washed once in PBS before mounted using Fluoromount-G and glass
coverslips (Invitrogen). Slides were sealed with nail-varnish.
2.8. Analysis of RGC somal death and degeneration
RGC loss and nuclear shrinkage was assessed through RBPMS and
DAPI labelling of flat mounts. Images were acquired on a Zeiss Axioskop
2 plus epifluorescence microscope (Karl Zeiss). Six images per retina
(40X magnification, 0.25 μm/pixel) were taken equidistant at 0, 2, 4, 6,
8, and 10 o’clock about a superior to inferior line through the optic
3
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curve (AUC) of the Sholl curve was calculated. Dendritic health and
integrity was evaluated by quantifying dendrite varicosities. Varicosities
were identified automatically by the spot tool and a density per cell
calculated by normalizing to total dendritic length and dendritic field
area.

the mass spectrometry peak and normalized to an internal standard for
negative and positive runs, then normalized to tissue weight. Data were
analyzed using MetaboAnalyst (version 4.0 [20,21]). Groups were
compared by two-sample t-tests with an adjusted P value (false discov
ery rate, FDR) cutoff of 0.05 deemed significant. Dendograms were
created using hierarchical clustering (HC) in R (1-cor, Spearman’s rho).
Heatmaps were created in R and using Morpheus (https://software.br
oadinstitute.org/morpheus). Principle component analysis was calcu
lated using Pareto scaling to reduce the effect of magnitude [22],
without excluding this dimension entirely. Pathways analysis was per
formed in MetaboAnalyst using the Rattus norvegicus KEGG library.
Circos plots were created in R using the circlize package [23], using
Spearman’s rank correlations with a P value adjusted for multiple
comparisons.

2.11. Mitochondrial RNA to nuclear RNA ratio
The ratio of RNA from genes encoded in the mitochondrial (mt) and
nuclear (nu) genome can differential expression of mitochondrial genes
or loss/gain of mitochondrial numbers [19]. Six C57BL/6J mouse retina
following 3 days ex vivo of the retina axotomy explant model, and six
0 DEV controls were homogenized into 400 μl buffer RLT (Qiagen) with
1% β-mercaptoethanol (Fisher Scientific) using a QIAshredder kit
(Qiagen) according to the manufacturer’s instructions. RNA was
extracted using RNeasy Mini Kits (Qiagen) according to the manufac
turer’s instructions. RNA was extracted into nuclease-free water, and
RNA concentration was measured in a 1 μl sample diluted 1:200 in
nuclease-free water in a spectrophotometer (BioPhotometer, Eppen
dorf). cDNA was synthesized using 1 μg of input RNA with an iScript™
cDNA Synthesis Kit and MyIQ thermocycler (both Bio-Rad) and stored at
− 20 ◦ C overnight. RT-qPCR was performed using 1 μg of input cDNA,
7.5 μl of SsoAdvanced Universal SYBR Green Supermix and 1 μl of the
following DNA templates (Prime PCR Assay, Bio-Rad): mt-Co2 (mito
chondrial; mus musculus), Rps18 (nuclear; mus musculus), and Tbp
(housekeeping; mus musculus). A MyIQ thermocycler was used with a 3
min activation and denaturation step at 95 ◦ C, followed by an amplifi
cation stage comprising 50 cycles of a 15 s denaturation at 95 ◦ C and 1
min annealing and plate read at 60 ◦ C. Analysis was performed ac
cording to the ΔΔCT method outlined by Quiros et al. [19] giving a
mtRNA:nuRNA ratio. ΔΔCTs were compared by student’s t-test.

2.13. Luminometry-based NAD assays
To measure NAD concentration in retina and optic nerves following
14 days of OHT, BN rats were anesthetized by intraperitoneal injection
of pentobarbital (75 mg/kg), and euthanized by cervical dislocation (n
= 6 eyes and optic nerves from NT, 6 eyes and optic nerves from OHT).
Whole eyes were removed and retina dissected in HBSS as described
above. The brain was removed with attached optic nerves. Optic nerves
were cut at the chiasm and 4 mm from the end proximal to the eye was
measured and collected and stored at 4 ◦ C in HBSS until further pro
cessing. Retinas were transferred to 500 μl of dispase (5000 U, Corning)
and put on a heating block (Thermomixer C, Eppendorf) at 37 ◦ C, 350
rpm for 30 min before dissociation by gentle trituration. Cell concen
tration was determined by cell counting on a hemocytometer (C-Chip,
NanoEntek) and each sample was diluted to a concentration of 2 million
cells/ml. Retina and optic nerve samples were then homogenized for 20
s, 30,000 min− 1 (VDI 12, VWR). NAD concentration was performed
using a bioluminescent assay (NAD/NADH Glo-™, Promega). Kit re
agents were prepared according to the manufacturer’s instructions.
NAD-standards were prepared in HBSS from a 2 mM NAD stock (no.
N8285, Sigma-Aldrich). Either 50 μl of sample (100,000 cells/well for
retina) or NAD standard were combined with 50 μl of reagent in a 96well plate (Nunc™ F96 MicroWell™ White Polystyrene plate, Thermo
Fisher Scientific). Luminescence was recorded at approx. 1 h from initial
mixing (plate shake in machine) to give sufficient time for the reaction
to occur and remain stable. Luminescent intensity was converted to NAD
concentration using the NAD standard curve. In order to assess how
quickly nicotinamide could be utilized by cells to increase NAD con
centration NAD assays were performed on treated retina, optic nerve,
and brain cortex. C57BL/6J mice (n = 4 mice) were euthanized by
cervical dislocation and eyes and optic nerve dissected as above with the
exceptions that retinas from left and right eyes were pooled to form a
single sample (giving a concentration after processing of 1.4 million
cells/ml) and where optic nerves were cut to 2 mm. Whole cortex was
removed, separated by hemisphere, transferred to 800 μl of dispase and
processed as for the retina above to achieve a concentration of 2 million
cells/ml. From each sample (retina, optic nerve and cortex) 4 aliquots of
cell homogenate were taken for incubation with NAM (0 mM, 0.1 mM,
10 mM) for either 0, 2, 4, or 6 h. NAM was added to the correct con
centration to the samples so that all incubation times would complete at
the same time point. The bioluminescent assay was then conducted as
above.

2.12. Metabolomics
BN rats were induced with OHT for 3 days or remained as NT con
trols (as described above). Rats were either pretreated with NAM (800
mg/kg/d) for 7 days (10 days total exposure) or were untreated (n = 8
eyes NT, n = 8 eyes OHT, n = 8 eyes NT-NAM, n = 8 eyes OHT-NAM).
Rats were euthanized by pentobarbital injection and cervical dislocation
(as described above). Retinas were immediately dissected on ice cold
HBSS (optic nerve head was not included), wiped dry and weighed
before snap freezing on dry ice. A second investigator removed the brain
and attached optic nerves immediately after death. Optic nerves were
separated at the chiasm and weighed before freezing as for retinas. The
superior colliculus (SC) was isolated and separated into left and right
hemispheres before weighing and freezing as for the retina. Tissue was
stored on dry ice and shipped to the Swedish Metabolomics Centre for
sample processing. 200 μl of 90:10 MeOH:H2O was added to each frozen
sample on dry ice, acid washed glass-beads (425–600 μm; Sigma
Aldrich) were added to constitute 50% v/v of the MeOH:H2O solution
and tissues were disrupted by shaking at 30 Hz for 3 min, followed by an
additional shaking step after the addition of 100 μl of H2O. Samples were
then centrifuged (14,000 RPM, 10 min, 4 ◦ C) and 100 μl of the super
natant was transferred to HPLC vials and immediately analyzed. 2 μl was
injected into an Agilent 1290 UPLC-system connected to an Agilent 6550
Q-TOF mass spectrometer with an Agilent Jet Stream electrospray
ionization (ESI) source. Data was collected in positive and negative
ionization mode. The HPLC column used was an HILIC (iHILIC-Fusion
(+), 100 × 2.1 mm, 3.5 μM, 100 Å, Hilicon AB). HILIC elution solvents
used were A) 50 mM ammonium formate in H2O and B) 90:10 Aceto
nitrile:[50 mM ammonium formate in H2O]. Chromatographic separa
tion at a flow rate 0.4 mL/min was achieved using the following linear
gradient: min 0 = 90% B, min 4 = 85% B, min 5 = 70% B, min 7 = 55%
B, min 10 = 20% B, min 10.01 = 90% B, min 15 = 90% B. Seventy three
low molecular weight metabolites that could be verified with standards
were detected. Metabolites were quantified as area under the curve of

2.14. Generation and characterization of MitoV mouse
MitoV mice were an independent founder (substrain 1819) in the
generation of transgenic mice described by Misgeld et al. and as detailed
by Burgess and Fuerst [24,25]. YFP is expressed under a rat Eno2 pro
moter (neuron specific) and localized to mitochondria via a Cox8a
gene-targeting signal fused to the YFP N-terminus. Mice are on a
C57BL/6J background. We selected this line based on specificity of inner
4
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retinal expression (designated MitoV for visual tissue). Four week old
mice were euthanized by cervical dislocation, eyes were enucleated and
fixed in PFA for 1 h, before performing immunofluorescent labelling as
described above with anti-GFP and anti-RBPMS antibodies. Brains were
fixed in PFA and processed for whole brain cryo-sectioning as described
above.

described and treated with NAM dissolved in the media at concentra
tions of 0, 50, 100, 500, and 1000 μM at day 7 post seeding. At eight days
post seeding, mitochondria were stained with MitoTracker Red CMXRos
(Molecular Probes, Invitrogen) for 30 min at 37 ◦ C. Using a Zeiss LSM
880 confocal microscope (63X oil immersion lens, 0.132 μm/px)
time-lapse imaging was performed in order to record mitochondrial
movement. Images were captured every 5 s for 10 min. Mitochondria
were classified as either stationary or moving over the 10 min recording
based on a total 5 μm distance threshold. Mitochondrial length (long
axis), and number of mitochondria (total, motile, stationary) in the
entire length of neurites in each group was measured in the first frame
(Fiji) and Kymographs of mitochondrial movements were generated
using the KymoAnlyzer plugin [28] for Fiji. Mitochondrial velocity was
calculated as distance travelled on the kymograph x axis divided by
length of the y axis (duration of movement).

2.15. Super-resolution fluorescent imaging of mitochondria and
morphological analysis
Super-resolution fluorescent images of mitochondria were captured
using Airyscan imaging on a Zeiss LSM800-Airy (63X, 1.3X optical
zoom, 66.76 × 66.76 μm images, 35 nm/pixel, z-stacks with 15 nm slice
thickness). For MitoV mouse tissue, images were acquired of Alexa Fluor
488 conjugated secondary antibodies targeting anti-GFP primary anti
body to limit loss of signal from potential YFP bleaching. To allow for
practical acquisition times, only the mitochondrial channel was imaged;
DAPI nuclear stain and RBPMS labelling in the same image window were
captured as snapshots only for reference purposes. Secondary antibody
only controls were used for all experiments to set suitable imaging pa
rameters. Retina axotomy explant was performed on MitoV retinas, with
4 retinas maintained for 0 DEV (control), 4 retinas for 0.5 DEV, and 4
retinas for 0.5 DEV with NAM supplemented media (500 mM). Retinas
were imaged as flat mounts, with 4 images collected at 1000 μm ec
centricity from the optic nerve head superiorly, nasally, inferiorly, and
temporally. Images were captured as z-stacks from the NFL to the lower
boundary of the GCL. The intravitreal rotenone injection model was
performed with 9 DMSO (vehicle only) injected retinas, 4 Rotenone (10
mM) injected retinas and 7 Rotenone injected retinas where animals
were pre-treated with NAM (500 mg/kg/d) for 1 week prior to injection
and maintained for the duration of the experiment. Eyes were enucle
ated 24 h after injection, fixed in PFA and processed for cryo-sectioning
as described above. 20 m cryosections were cut and immunofluorescent
labelling performed using Alexa Fluor 488 conjugated secondary anti
bodies targeting anti-GFP primary antibody. Airyscan images were ac
quired of central retina ~500 μm later to the optic nerve head,
encompassing the NFL, GCL and inner plexiform layer (IPL). The IPL was
cropped for analysis. In rat tissue, 5 NT eyes (from 3 rats), 6 OHT eyes
(from 4 rats) and 4 OHT-NAM (from 4 rats, pre-treatment with 800 mg/
kg/d NAM) were collected 14 days after OHT induction and processed
for cryo-sectioning as described above. Alexa Fluor 568 conjugated
secondary antibodies targeting anti-TOMM20 primary antibodies was
imaged. Image capture and analysis followed the same protocol as for
rotenone injected eyes. IPL and GCL/NFL crops were analyzed sepa
rately. In all three models, mitochondria were reconstructed in 3D using
Imaris software (version 9.3.1). Volume reconstructions were performed
using the surfaces tool and individual volume and surface area were
calculated. Volumes <125 voxels were filtered and removed from sub
sequent analysis to reduce noise.

2.17. Extracellular acidification rate and oxygen consumption rate
RGCs were purified from mice according to the methods previously
described by Skytt et al. and Vohra et al. [29,30]. Culture media was a
combination of Neurobasal A medium and DMEM, supplemented with
glucose to reach a final concentration of 6 mM, and with pen
icillin/streptomycine, sato, T3, B27, NAC, Trace elements B, biotin,
CNTF, BDNF, forskolin, FGFB, and insulin as described in the references
above. RGCs were cultured in a Seahorse 96-well cell culture microplate
at a density corresponding to 450,000 cells/cm2. Glycolytic and mito
chondrial respiratory function was measured using real-time assessment
of, respectively, the extracellular acidification rate (ECAR) and oxygen
consumption rate (OCR) with the Seahorse XFe96 Extracellular Flux
Analyzer (Seahorse Biosciences-Agilent Technologies, USA) after one
week. On the day prior to the assay, cells were pre-incubated 24 h before
the analysis under the different experimental conditions: Control (0 μM
nicotinamide (NAM)), 50 μM NAM, 500 μM NAM and 1000 μM NAM in
culture media as above (no pyruvate, no glutamine) Prior to the assay,
culture media was changed to CO2 calibrated Seahorse XF DMEM (un
buffered, adjusted to pH 7.4, supplemented with glucose to reach a final
concentration of 6 mM) and the cells were equilibrated for 15 min at
37 ◦ C in a CO2-free incubator. Time of calibration inside the seahorse
instrument was set for further 15 min. Each OCR measurement cycle
consisted of 3-min mix and 3-min measurement of the oxygen level, as
well as ECR. The analysis of glycolytic and mitochondrial function was
initiated by three baseline OCR measurement cycles. The pH of the re
agents used to test mitochondrial function was adjusted to 7.4. The OCR
and ECR were recorded and calculated by the Seahorse XFe96 software,
Wave (Seahorse Biosciences-Agilent Technologies, USA). To normalize
the data after the Seahorse analysis, the protein content for each well
was measured using a BCA assay with BSA as standard. Measurements
were acquired for 3–5 different cell batches per condition.
2.18. Whole-cell patch-clamp electrophysiology

2.16. Live-imaging of mitochondria

C57BL/6J mice (12 weeks) were anesthetized with 2% isoflurane
and cervically dislocated. Eyes were enucleated and placed into cutting
solution consisting of (mM): 125 Choline-Cl, 2.5 KCl, 0.4 CaCl2, 6 MgCl2,
1.25 NaH2PO4, 26 NaHCO3, 20 D-glucose, on ice and saturated with 95%
O2 plus 5% CO2. The cornea was pierced with a 30 G needle and the
retina dissected out. The retina was then incubated for 2 h at room
temperature in Ames medium (Sigma Aldrich; AUS) and 1.9g sodium
bicarbonate (Sigma Aldrich; AUS) with either 1 mM, 10 mM or 100 mM,
or 250 mM NAM (Sigma Aldrich; AUS) or control solution saturated with
95% O2 and 5% CO2. Retina were transferred to a submerged recording
chamber on an upright microscope (Slicescope Pro 1000; Scientifica,
UK). For all recordings, retina were perfused (2 ml/min) with Ames
medium saturated with 95% O2 plus 5% CO2 at 24 ◦ C, containing either
1 mM, 10 mM, 100 mM or 250 mM NAM or control (0 mM) solution as
per the previous incubation step. The center of the retina was located

RGC cultures were established according as previously described
([26], modified from [27]). Six to seven day old C57BL/6J pups were
euthanized and retinas dissected (n = 16–18 per panning procedure, 3X
repeats). Retinas were dissociated in DPBS (Thermofisher, UK) by for
ceps within 35 min at room temperature under 4X dissecting microscope
followed by gentle trituration. RGCs were purified using two-step
immune-panning on two Lectin coated negative panning plates (Ban
deiraea simplicifolia, BSL-1; Vector Laboratories Ltd.) and a Thy1.2
antibody coated positive plate (Serotec MCA02R, Bio-Rad), over 45 min
at room temperature (25 ◦ C). RGCs were seeded at a density of 50,000
cells per well (24 well plate; Nunc, Thermofisher) on Poly-D-lysine and
laminin coated glass coverslips (Sigma-Aldrich, R&D Systems, and
Academy Science Limited, respectively). RGCs were cultured in
serum-free growth medium (37 ◦ C, 10% CO2) for 10 wells as previously
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using infrared-oblique illumination microscopy with a 4x air objective
(Olympus, Japan) and a CCD camera (IEEE 1394; Foculus, Germany)
and retinal ganglion cells visualized using a 40 × water-immersion
objective (Olympus, Japan). Retinal ganglion cells with large cell bodies
were chosen and their identity confirmed by the presence of AP firing
and post-hoc biocytin immunohistochemistry (detailed below). Patch
pipettes (6–9 MΩ; GC150F-7.5; Harvard Instruments; USA) were pulled
using a Flaming/brown micropipette puller (Model P-1000; Sutter in
struments, USA) and filled with solution containing (mM): 115 K-glu
conate, 5 KCl, 5 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, and 7
phosphocreatine (pH 7.3). Once whole-cell configuration was obtained,
a holding current was injected to maintain a holding potential of
approximately − 60 mV. Cells were excluded if a holding current greater
than − 100 pA was required to achieve a membrane potential of − 60 mV.
Patch clamp recordings were performed using a PatchStar microma
nipulator (Scientifica, UK) and Axon Multiclamp 700B patch-clamp
amplifier (MDS, USA). Current clamp data were acquired using
pClamp software (v10; MDS, USA) with a sampling rate of 100 kHz and
low pass Bessel filtered at 10 kHz (Digidata 1440a; Axon). Action po
tential firing was recorded using an episodic protocol with the following
current steps (0–200 pA in 10 pA steps, 400 ms duration, 5s inter sweep
interval).

3. Results
3.1. Nicotinamide confers retinal ganglion cell neuroprotection in a range
of glaucoma-relevant contexts
Nicotinamide is protective in a genetic mouse model (DBA/2J) that
recapitulates features of a human pigmentary glaucoma and demon
strates an age-related decline in retinal NAD [5]. To further determine
how nicotinamide (NAM) protects retinal ganglion cells (RGCs), we
induced RGC degeneration in two separate glaucoma relevant insults in
the absence of an age related effect: elevated IOP and optic nerve
degeneration induced by axotomy. We first confirmed the neuro
protective effects of NAM in an inducible, acute rat model of glaucoma
where the onset of high IOP is controlled and abrupt. Restriction of the
anterior chamber drainage structures via magnetic microbead injection
limits aqueous humor fluid outflow, producing significant ocular hy
pertension (OHT; elevated intraocular pressure) which is sustained for
two weeks (Fig. 1A). NAD was significantly reduced in the retina and
optic nerve of OHT animals at 14 days post-induction (Fig. 1B) (i.e.
IOP-dependent, not age-dependent NAD decline). In vivo imaging using
optical coherence tomography (OCT) demonstrated loss of the neuro
retinal rim (representing intra-retinal retinal ganglion cell axons;
Fig. 1C). Rats pre-treated with NAM (200 mg/kg/d dietary, represen
tative of 2 g/d for a 60 kg human [31]; with treatment continuing for the
duration of OHT) did not demonstrate loss of the neuroretinal rim
despite maintaining a similar IOP (Fig. 1C). OHT eyes demonstrated
significant RGC loss as assessed by RBPMS + counting (an RGC specific
marker in the retina, Fig. 1D). The average RGC nuclear diameter
(RBPMS + DAPI nuclei) was also significantly decreased, suggesting that
surviving cells were under considerable neurodegenerative stress
(Fig. 1E) [32]. NAM treated OHT rats demonstrated significantly
reduced RGC loss and nuclear shrinkage in a dose dependent manner
(200, 400, or 800 mg/kg/d dietary, representative of 2, 4, or 8 g/d for a
60 kg human [31]; Fig. 1E). These data support a neuroprotective role
for NAM in the context of high IOP without an associated age-related
NAD decline.
We next tested NAM protection in an acute, axon-specific injury
using a retinal explant model [12,13]. Enucleation severs RGC axons in
the optic nerve, and explants maintained in culture ex vivo, demon
strated a progressive RGC loss and nuclear shrinkage observed within
12 h, with highly significant, reproducible RGC loss at 3 days ex vivo
(Fig. 2A and B, Supplementary Fig. 1 A and B). This RGC loss and nu
cleus shrinkage is robustly prevented by NAM-supplemented media at a
range of doses. Using this explant model we assessed whether protection
extended to RGC axons and dendrites. RGC axons within the retinal
nerve fiber layer (RNFL) demonstrated a significant increase in the
number of varicosities, a metric of neurite degeneration, by 3 days ex
vivo, but with no change in average varicosity size (Fig. 2C and D,
Supplementary Fig. 1C and D). These changes were not observed in NAM
treated retina, even by 3 days ex vivo, demonstrating significant pro
tection against severe acute axon degeneration (Fig. 2C and D). At 3 days
ex vivo RGCs had significant dendritic atrophy compared to control
retina (0 days ex vivo), with reduced complexity (as assessed by Sholl
analysis), total dendritic length, and dendritic field area. NAM treatment
was highly effective, preserving dendritic morphology (Fig. 2E and F).
Dendritic varicosities were significantly increased in density as a func
tion of dendrite length and dendritic field area, indicating dystrophy and
degeneration of dendrites. NAM at a range of doses prevented these
changes (Fig. 2E and F). These data support previous findings on the
protective effects of NAM, and extend its known effects to encompass
neuroprotection across RGC compartments within the retina in addi
tional animal models.

2.19. Analysis of action potential firing
Data were analyzed using AxoGraph X software (Berkeley, CA, USA).
Action potentials were detected using an amplitude threshold of 50 mV
relative to pre-event baseline. Input-output curves were calculated by
determining the number of action potentials generated for each injected
current step. All action potential kinetics were analyzed for the first
action potential at rheobase current, defined as the minimum current
injection required to generate an action potential. Action potential
threshold was defined as 30 mV/s. Action potential amplitude was
calculated relative to pre-event baseline. Action potential half-width
was calculated at 50% of maximal action potential amplitude. The ac
tion potential rise-time was calculated as the time between 20% and
80% of the maximal action potential amplitude.
2.20. Biocytin immunohistochemistry and morphological analysis
Following the completion of recordings, retina were removed, fixed
in 4% paraformaldehyde in 1 M phosphate buffer overnight at 4 ◦ C then
washed three times for 5 min in 1 M phosphate buffer. Retina were
incubated overnight at room temperature in Alexa Fluor 488 streptavi
din (S11223, ThermoFisher Scientific, USA). Retina were mounted using
ProLong Gold Antifade Mountant (P36930, ThermoFisher Scientific,
USA) and z-stack images were acquired on a Zeiss LSM 780 confocal
microscope (Zeiss, Germany). Whole dendritic arbors were recon
structed using Imaris as above. Sholl analysis and dendritic field area
measurements were generated in Imaris and soma diameter was
measured on z-projections in Fiji (using the longest axis).
2.21. Statistical analysis
All statistical analysis was performed in R. Data were tested for
normality with a Shapiro Wilk test. Normally distributed data were
analyzed by Student’s t-test or ANOVA (with Tukey’s HSD). Nonnormally distributed data were transformed using squared transforms;
data that remained non-normally distributed was analyzed by a KruskalWallis test followed Dunn’s tests with Benjamini and Hochberg correc
tion. Unless otherwise stated, * = P < 0.05, ** = P < 0.01, ***P < 0.001,
NS = non-significant (P > 0.05). For box plots, the center hinge repre
sents the mean with upper and lower hinges representing the first and
third quartiles; whiskers represent 1.5 times the interquartile range.
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Fig. 1. Nicotinamide provides neuroprotection in a rat bead model of ocular hypertension. (A) Ocular hypertension (OHT; n = 26 eyes) induced by the
magnetic bead injection lead to a significant increase in IOP over control (NT; n = 20 eyes), which persisted for 14 days (greater than 2 standard deviations of NT,
blue line). Nicotinamide (NAM) treatment in OHT animals (200, 400, 800 mg/kg/d; n = 10, 12, and 24 eyes respectively) did not lower IOP (as assessed by area
under the IOP curve). (B) Following 14 days of sustained OHT, NAD was significantly reduced in both the retina (n = 6) and optic nerve (n = 6) as measured by
luminometry-based assays. (C) In vivo OCT imaging demonstrated significant loss of neuroretinal rim following 14 days OHT (n = 7 eyes) compared to NT eyes (n =
9), which was absent in NAM treated rats (n = 8 eyes; measured as the cup depth relative to retinal thickness; loss denoted by white * on example image). (D) RBPMS
(RGC specific) and DAPI labelling of the retina demonstrated a dose dependent, significant neuroprotection against RGC loss and RGC nuclear shrinkage at day 14 (E;
n = 10 NT retinas, 10 OHT, 9 OHT-NAM (200 mg/kg/d), 12 OHT-NAM (400 mg/kg/d), and 12 OHT-NAM (800 mg/kg/d)).Scale bar = 100 μm in C, 20 μm in D. **P
< 0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

3.2. Nicotinamide alters metabolic profiles in normal, non-diseased
retinal ganglion cells

conditions. We optimized a low molecular weight mass spectrometry
platform to assess 73 essential low molecular weight metabolites across
the RGC trajectory in normotensive rats (NT; normal IOP, no disease).
We used bulk tissue (rat retina, optic nerve, superior colliculus (SC; the
major RGC terminal in the rodent)) to avoid metabolic changes induced
by cell sorting or tissue processing protocols. These data provide a novel
metabolome across RGC compartments; dendrites, soma, and

Given the importance of NAD in a wide array of metabolic processes
and the potential of NAM as an interventional and prophylactic treat
ment in human glaucoma, we sought to determine whether NAM
treatment alters RGC metabolic profiles under normal physiological
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Fig. 2. Nicotinamide protects against axonal and den
dritic degeneration. (A) Retinal axotomy explant results
in significant RGC death and nuclear shrinkage, at 3 days
ex vivo (DEV) with robust protection provided by NAM
treated media (B; n = six 0 DEV retinas, six 3 DEV un
treated, six 3 DEV-NAM (100 mM), eleven 3 DEV-NAM
(500 mM)). (C) β-tubulin labelling reveled a significant
increase in axonal varicosities within the retinal nerve fiber
layer at 3 DEV, which were robustly protected against by
NAM (D; n = six 0 DEV retinas, six 3 DEV untreated, six 3
DEV-NAM (100 mM), six 3 DEV-NAM (500 mM)). (E and
F) At 3 DEV significant changes to the complexity of the
dendritic arbor were apparent (E; example RGCs labelled
by DiOlistics). At 3 DEV there was a loss of branch density
(reduction in Sholl AUC), a reduction in dendritic length
and field area. NAM treated media provided significant
protection against these neurodegenerative features (n =
75 RGCs from ten 0 DEV retinas, 46 RGCs from twelve 3
DEV untreated, 53 RGCs from twelve 3 DEV-NAM (100
mM), 62 RGCs from twelve 3 DEV-NAM (500 mM)). At 3
DEV dendrites display an increased density of varicosities,
which was protected against by NAM (F; n = 55 RGCs from
0 DEV retinas, 23 RGCs from 3 DEV untreated, 38 RGCs
from 3 DEV-NAM (100 mM), 32 RGCs from 3 DEV-NAM
(500 mM)). Scale bar = 20 μm in A, 50 μm in C and E.
*P < 0.05, **P < 0.01, ***P < 0.001.
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unmyelinated axons (retina), myelinated axons (optic nerve), and ter
minal arbors (SC) (Supplementary Dataset 1 and 2; raw and normalized
data). The normal rat metabolome varies significantly by these selected
regions, with all 73 metabolites differentially abundant across tissues.
Unsupervised hierarchical clustering (HC) separated samples into
discrete groups that matched the different tissues, confirming globally
distinct metabolic profiles (Supplementary Fig. 2A). Metabolites were
most highly abundant in the optic nerve, followed by the SC and retina
respectively. Correlation of all individual metabolites for all samples
demonstrated that the SC had the highest intra-tissue correlation
(Fig. 3A). In order to identify distinct metabolic signatures of the
discrete tissues we used principle component analysis (PCA). Unsuper
vised PCA separated samples into discrete tissue groups supporting the
HC data with PC1 describing the vast majority of variation (95.3%;
Fig. 3B). Creatine, hypotaurine, 2-aminobutyric acid, glycer
ophosphocholine, and cysteine were the highest contributing loading
factors in to PC1 demonstrating that relative abundance remained the
largest determinant of tissue type even after scaling to reduce its effects
(Supplementary Fig. 2B and C). We specifically queried how NAD,
NADH, and NAM vary across these tissues. NAD was higher in retina and
optic nerve than in the SC, but NADH was much more abundant in the
optic nerve. This results in a lower NAD:NADH ratio in the optic nerve.
NAM was relatively low in the retina compared to both the optic nerve
and SC (Fig. 3C).

NT rats treated with NAM 10 days prior to metabolomic analysis
demonstrated a small but statistically significant reduced IOP of − 1.2
mmHg (the physiological impact of which is likely to be limited)
(Fig. 4A). (It is important to note that NAM treatment did not affect IOP
in the context of OHT; Fig. 1A.) HC of individual samples demonstrated
that NT-NAM treated retina were largely similar to normal NT retina,
but there was a clear distinction in metabolic profile in the optic nerve
and SC (Fig. 4B). PCA demonstrated that NAM induced changes were not
sufficient to drive group distinction (Fig. 4B). NAM treatment resulted in
9 changed metabolites (11%) in the retina, 24 in the optic nerve (30%),
and 5 in the SC (6%) (Fig. 4C–F, Supplementary Dataset 3). Increased
NAD, NADH, and threonine were common to all tissues, with glyceric
acid also increased in both retina and optic nerve (Fig. 4G, Supple
mentary Fig. 3). These metabolites alone were sufficient to distinguish
NT and NT-NAM samples by HC (Fig. 4G). NAM was only increased in
the optic nerve, suggesting that conversion to NAD may be saturated in
the optic nerve at this dose (Supplementary Fig. 3). The NAD:NADH
ratio was only significantly altered in the optic nerve (40% increase), as
NAD was increased to a greater proportion than NADH (~2.4 fold
compared to ~1.7 fold), suggesting a larger pool of free NAD (Supple
mentary Fig. 3). Pathways analysis revealed that NAM induced changes
are predicted to significantly impact nicotinate and nicotinamide
metabolism across the retina and optic nerve (Fig. 4H, Supplementary
Dataset 4). Arginine biosynthesis is predicted to be affected in the retina,

Fig. 3. Metabolic profiles of retinal ganglion cell related tissues. (A) Seventy three low molecular weight metabolites could be reliably detected in retina (n = 8),
optic nerve (n = 8) and superior colliculus (SC; n = 8 hemispheres) of Brown Norway rats. Within tissue correlation of metabolites is demonstrated by a circus plot
with linkers between metabolites. The number of significantly correlated metabolites is shown as a bar graph in the outer circle. The SC (pink) showed the greatest
degree of within tissue correlation of metabolites. (B) Tissue differences were explored by principle component analysis (PCA) which revealed a clear distinction of
tissues predominantly along one component (PC1). (C) NAD and related metabolites NADH and nicotinamide were compared between tissues. The optic nerve was
most abundant in NAD, NADH, and nicotinamide but had the lowest NAD:NADH ratio, whilst the retina was comparatively low in nicotinamide, and the SC
comparatively low in NAD and NADH. **P < 0.01, ***P < 0.001, NS P > 0.05. (For interpretation of the references to color in this figure legend, the reader is referred
to the Web version of this article.)
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Fig. 4. Nicotinamide alters metabolic profile of retinal ganglion cell related tissues. (A) High dose nicotinamide supplementation resulted in small significant
decrease in IOP on average in NT eyes (n = 60 NT eyes, 40 NT-NAM (800 mg/kg/d) eyes). (B) BN rats were either untreated (NT) or maintained on NAM for 1 week
(NT-NAM, 800 mg/kg/d) before metabolomics analysis of tissue. Unsupervised hierarchical clustering (HC) showed no clear distinction between NAM treated and
untreated NT retina metabolic profiles (n = 8 NT retina, 8 NT-NAM), but clear separation in the optic nerve (n = 8 NT optic nerves, 8 NT-NAM) and superior
colliculus (n = 8 NT SC hemispheres, 8 NT-NAM; all scaled where red = high correlation, blue = low correlation). Principle components analysis (PCA) showed little
discriminating power indicating limited large scale NAM induced changes (NT = black, NT-NAM = red). (C) Comparison of NT and NT-NAM treated tissue revealed a
number of significantly changed metabolites in D retina, E optic nerve, and F) superior colliculus (FDR < 0.05; red = increased in NT-NAM, blue = decreased), with
the optic nerve the most changed. (G) Comparison of significantly changed metabolites across tissues revealed NAD, NADH, threonine, and glyceric acid (later in
retina and optic nerve only) to be commonly increased (Euler plot showing total changed metabolites, with the number of common changed metabolites between
tissues denoted in red). (G) HC dendograms and heatmaps (where red = highest value, blue = lowest value by row) demonstrate the clear difference in these
metabolites between NAM treated and untreated retina, optic nerve ad superior colliculus. (H) Pathways analysis (KEGG) demonstrated that the changed metabolites
(in D-F) resulted in minimal pathway changes of significant impact in the retina, and none in the superior colliculus. In the optic nerve, changes were predicted
predominantly to NAD and related metabolite pathways. Pathways are highlighted red where FDR <0.05, and annotated when in conjunction with high impact (i.e.
predicted knock-on effects to the pathway); size denotes the number of metabolites within the pathway (scale adjacent). **P < 0.01. (For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this article.)
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and phenylalanine, tyrosine and tryptophan biosynthesis, taurine and
hypotaurine metabolism, alanine, aspartate and glutamate metabolism,
D-glutamine and D-glutamate metabolism, and glycine, serine and thre
onine metabolism are predicted to be altered in the optic nerve. In these
pathways, significant impact was attributed predominantly to NAM and
NAD or amino acids L-threonine, L-glutamate, L-aspartate, and phenyl
alanine. There were no predicted pathway changes in SC dataset
(Fig. 4H). When cultured in NAM, dissociated neurons from retina, optic
nerve, and cortex produce increased NAD over untreated cells demon
strating the ability to rapidly and directly metabolize NAM to NAD
without the need for first pass metabolism (Fig. 5).

optic nerve demonstrated 16 commonly changed metabolites that reflect
NAM specific changes (Fig. 6G). HC using only these 16 metabolites was
sufficient to separate individual NAM treated groups from untreated
groups. Comparison of these changed metabolites relative to NT
demonstrated marked increases in NT-NAM only, with OHT-NAM
retuned to NT levels across all metabolites (with the exception of NAD
and threonine) (Fig. 6G). Crucially, NAD, NADH, and NAM remained
higher in OHT-NAM optic nerves than in untreated OHT optic nerves
(Supplementary Fig. 4B). As high NAD is axon protective [33], then this
suggests that there is likely to be a longer term neuroprotection to the
optic nerve afforded by NAM. However, this will need to be definitively
tested at later disease time points than those explored here.
In the SC, NAM treated conditions were clearly distinguished by HC
(Fig. 6H). During OHT 6 metabolites declined relative to NT controls, of
which 5 of these changes were prevented in OHT-NAM (Fig. 6I). NAM
treatment in OHT was sufficient to replete NAD in the SC, with a
diminished increase over normal NT levels relative to NT-NAM (Sup
plementary Fig. 4C). The small number of metabolite changes in the SC
were insufficient to drive any predicted pathways changes.
Comparison of changes in OHT across tissues revealed 5 commonly
changed metabolites in the retina and SC (Fig. 6J). Of these, all were
changed in opposing directions, demonstrating a concomitant increase
in the retina and decrease in the SC. These data support a hypothesis in
which RGC metabolism is altered early during glaucoma pathogenesis
and that this is largely prevented or buffered by oral NAM
administration.

3.3. Nicotinamide protects against metabolic disruption following ocular
hypertension
In order to determine the NAD and metabolic changes that may
precede RGC death we performed metabolomics following 3 days of
OHT, a time point at which IOP is high but no detectable RGC loss has
occurred [11]. The retinal metabolome is significantly altered at this 3
day time point. HC revealed heterogeneity across and within conditions,
but with a division between samples such that NAM treated eyes were
largely grouped and distinguished (Fig. 6A). In the retina OHT led to 25
changed metabolites relative to NT controls (24 increased, 1 decreased).
Notable changes were increased alpha-ketoglutaric acid, homocysteine,
threonine, NAD, and glycerophosphocholine, while creatinine was the
sole reduced metabolite (Fig. 6B). Comparison of OHT-NAM treated
retinas to NT-NAM (thus excluding normal NAM induced changes)
revealed that NAM treatment completely prevented any OHT induced
metabolite changes (Fig. 6B). NAD remained high in OHT-NAM retinas
(Supplementary Fig. 4A). Pathway analysis predicted changes to
alanine, aspartate and glutamate metabolism, D-glutamine ad D-gluta
mate metabolism, arginine biosynthesis, glyoxylate and dicarboxylate
metabolism, and histidine metabolism (Fig. 6C).
In the optic nerve, HC revealed discrete untreated and NAM groups
(Fig. 6D). No metabolites were significantly changed in OHT relative to
NT (Fig. 6E). In OHT-NAM, 24 metabolites were significantly lower than
in NT-NAM. Comparison of OHT-NAM to untreated OHT and NT
demonstrated only 2 and 4 changed metabolites respectively (Fig. 6F).
Collectively, these data suggest that the NAM induced metabolic profile
change exhibited in normal tissue is lost during OHT. Comparison of
NAM changes in NT (NT vs. NT-NAM) and OHT (NT-NAM vs. OHT-NAM)

3.4. Nicotinamide protects retinal ganglion cells from metabolic crisis
We have previously demonstrated dysregulated gene expression in
RGCs across multiple metabolic pathways [5], including widespread
upregulation of genes encoding oxidative phosphorylation (OXPHOS)
proteins. Given that genetic changes coincide with mitochondrial cristae
loss and increased cytochrome c, it can be hypothesized that these may
reflect an upregulated transcriptional response in order to increase
mitochondrial OXPHOS capacity. Gene expression in axotomized retina
demonstrated a reduction in the mitochondrial-RNA:nuclear-RNA ratio
suggesting a loss of mitochondrial capacity or a reduced number of
mitochondria (Fig. 7A). We queried whether the ratio of ATP:ADP was
reduced in OHT, which would indicate a switch towards glycolysis from
OXPHOS, and how this may be affected by NAM treatment. No signifi
cant changes in this ratio were detected in the retina or optic nerve at 3
days in the rat OHT model. In the SC, the ATP:ADP ratio was signifi
cantly reduced in OHT and this was prevented by NAM treatment
(Fig. 7B). Since within condition variability was high, which may reflect
mixed cell type-specific responses, we analyzed OXPHOS and glycolysis
in purified mouse RGC cultures with NAM supplementation. Oxygen
consumption rate was significantly increased in cells supplemented with
50 and 500 μM NAM, with the effect diminished at higher concentra
tions. No significant change in extracellular acidification rate was
detected (Fig. 7C). These findings suggest that NAM supplementation
increases RGC OXPHOS capacity. We therefore tested the ability of NAM
to protect RGCs against OXPHOS inhibition using an intravitreal rote
none model (Complex I inhibition which results in the rapid degenera
tion of RGCs). Intravitreal injection of rotenone induced significant RGC
death within 1 day, which was significantly reduced by NAM supple
mentation (Fig. 7D and E). Thus, in the absence of axon degenerative
stress, nicotinamide can provide a robust neuroprotection against
mitochondrial stress.

Fig. 5. Nicotinamide can be rapidly metabolized to NAD by retina, optic
nerve, and brain tissue. Luminometry-based NAD assays on retina, optic
nerve and cortex incubated with NAM showed that it can be converted to NAD
within hours, increasing with increased exposure, suggesting an increase in the
NAD pool (n = 4 retinal replicates where each is composed of 2 pooled retinas,
for each time point a sample was taken from each replicate; n = 4 optic nerve
replicates where 8 optic nerves were divided in to 1 mm segments to give 16
independent samples for each time point; n = 4 cortex replicates where each
replicates is a single cortex hemisphere and for each time point a sample was
taken from each replicate). Optic nerve demonstrated the largest increase over
control (untreated optic nerve) supporting the metabolomics observations.

3.5. Nicotinamide increases mitochondrial size and motility
Mitochondrial remodeling and/or loss is a common feature of
neurodegenerative disease which may drive neuronal metabolic
dysfunction. We directly assessed changes to mitochondrial morpho
logical integrity after 14 days of OHT in the rat. TOMM20 labelled
11
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Fig. 6. Nicotinamide prevents metabolic disruption. The metabolic profiles of BN rats following 3 days of OHT (prior to detectable neurodegeneration) were
compared to NT controls, and the effects of pretreatment with NAM (800 mg/kg/d) explored (n = 8 retinas, optic nerves and superior colliculus hemispheres for each
condition). (A) In the retina, unsupervised hierarchical clustering (HA) demonstrated that samples largely clustered based on exposure to NAM, but with hetero
geneity across conditions (heatmap scaled where red = high correlation, blue = low correlation). (B) OHT induced a number of metabolic disturbances with a
number of significantly increased metabolites (NT vs OHT; FDR < 0.05; red = increased in NT-NAM, blue = decreased; further shown in HA dendogram and
heatmap; red = highest value, blue = lowest value by row); these changes were completely absent in NAM treated retinas (NT-NAM vs OHT-NAM; which controls for
NAM specific effects). (C) Pathways analysis (KEGG) demonstrated a number of potentially effected pathways (pathways are highlighted red where FDR < 0.05, and
annotated when in conjunction with high predicted impact, size denotes the number of metabolites within the pathway). (D) In the optic nerve, HA revealed clear
distinction between NAM treated and untreated samples, irrespective of disease grouping. (E) No metabolites were significantly altered compared to NT following 3
days of OHT (NT vs OHT). (F) While NT-NAM treated optic nerves demonstrated a number of significantly changed metabolites over NT nerves, these effects were
lost under OHT as demonstrated by the reversal of a number of these changes (NT-NAM vs OHT-NAM) and the similar profiles of OHT-NAM optic nerves to both OHT
and NT nerves (OHT vs OHT-NAM, NT vs OHT-NAM respectively). (G) Comparison of NT-NAM vs OHT-NAM changes against NT vs NT-NAM changes, demonstrated
16 commonly changed metabolites (Euler plot showing total changed metabolites, with the number of common changed metabolites between comparisons denoted
in red). HA of these metabolites separated individual NAM treated groups from controls, and plotting the mean abundance of these relative to NT control further
highlights NAM specific changes that were reversed under OHT. (H) In the superior colliculus, HA largely distinguished individual groups, suggesting well defined
metabolic profiles per condition. (I) In the SC, OHT resulted in a significant decrease of metabolites (NT vs OHT), which was prevented by NAM treatment (NT-NAM
vs OHT-NAM). NAD in the SC was lower in OHT-NAM treated than NT-NAM treated (but remained above NT and OHT control levels; Supplementary Fig. 4). (J)
Comparison of OHT changes relative to NT in the retina, ON and SC revealed that 5 metabolites were commonly changed, where increases in the retina were mirrored
by decreases in the superior colliculus (Euler plot showing total changed metabolites, with the number of common changed metabolites denoted; for mean fold
change plot, red = increase, blue = decrease). *P < 0.05, **P < 0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)

Fig. 7. Nicotinamide buffers against metabolic crisis. (A) RGC axotomy resulted in a decrease in mitochondrial: nuclear derived RNA (mtRNA:nuRNA; relative
expression of mtCo2 and rps18) suggesting a loss of mitochondrial capacity or reduced numbers of mitochondria (n = five 0 days ex vivo (DEV) retinas, five 3 DEV).
(B) The ratio of ATP:ADP was not significantly altered in the retina or optic nerve, but was reduced under OHT in the superior colliculus which could indicate a
switch towards favoring glycolysis over oxidative phosphorylation (OXPHOS; n = 8 retina, optic nerve and superior colliculus hemispheres per condition). This was
reversed under NAM treatment. (C) Oxygen consumption rate was significantly increased in cultured RGCs supplemented with 50 and 500 μM NAM, suggesting NAM
increases OXPHOS capacity (n = 5 cultures with 0 μM NAM, 5 cultures with 50 μM NAM, 4 cultures with 500 μM NAM, and 4 cultures with 1000 μM NAM).
Extracellular acidification rate did not change significantly (n = 3 cultures per condition). (D and E) Intravitreal injection of rotenone (causing rapid depletion of
OXPHOS) caused significant loss of RGCs after 24 h, and pre-treatment with NAM provided significant protection against this loss (n = 8 retina per condition). Scale
bar in D = 20 μm *P < 0.05, **P < 0.01, ***P < 0.001.

mitochondria were imaged by super-resolution Airy confocal micro
scopy and reconstructed (Fig. 8A). Mitochondrial volume and surface
area were significantly reduced in the ganglion cell layer (GCL) and
RNFL (comprising RGC soma and axons and other retinal neurons/glia)
of OHT rats (Fig. 8B). NAM treatment partially protected from these
mitochondrial degenerative changes. In OHT rats, mitochondrial vol
ume and surface area were significantly increased in the IPL (comprising
RGC dendrites and interneuron neuropil), and further increased in OHTNAM treated rats (Fig. 8C). These different changes between retinal
layers may be representative of the various cell types that make up these
layers, their neuronal networks, and/or how they respond to OHT. To
determine RGC specific mitochondrial responses to injury and NAM, we
utilized a novel mitochondrial reporter mouse where YFP is expressed
under a rat Eno2 promoter (neuron specific) and localized to mito
chondria via a Cox8a gene-targeting signal fused to the YFP N-terminus
(neuronal expression shown in Supplementary Fig. 5). In this strain

(designated MitoV; for visual system tissue), YFP expression is RGC
specific in the inner retina, allowing the assessment of mitochondria
specifically in RGCs (with expression in a subset of bipolar cells and
photoreceptor outer segments which can be optically dissected; Sup
plementary Fig. 5A–C). We hypothesized that physical axonal damage
and mitochondrial stress work in concert to drive vision loss in glau
coma. To assess each of these in an isolated context, we induced RGC
axotomy (uncoupling the RGC from the terminal visual thalami) or
acute, severe mitochondrial dysfunction (intravitreal rotenone injec
tion). Using the retinal explant model to induce an RGC specific injury,
we assessed mitochondrial morphology in the GCL/RNFL (Fig. 9A). At
12 h ex vivo mitochondrial volume and surface area were significantly
increased. NAM supplementation of the media exaggerated the increase
in mitochondrial volume and surface area (Fig. 9B). Intravitreal injec
tion of rotenone resulted in a significant reduction of mitochondrial
volume and surface area in the IPL at 1 day post injection. NAM
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Fig. 8. Mitochondrial size changes following OHT. (A) Rat retina following 14 days of OHT (untreated (OHT, n = 6 retina) and NAM treated (800 mg/kg/d, OHTNAM, n = 4 retina)) and NT control (n = 4 retina) tissue was cryo-sectioned, mitochondria labelled by anti-TOMM20, and imaged by Airy confocal scanning mi
croscopy. The ganglion cell layer/retinal nerve fiber layer (GCL/RNFL) and inner plexiform layer (IPL) were analyzed separately (boundaries demarcated by white
broken lines). (B) Mitochondrial volume and surface area were significantly reduced under OHT in the GCL/RNFL and this was mitigated by NAM (n = 535
disconnected volumes in NT, 490 in OHT, 652 in OHT-NAM). (C) In the IPL mitochondrial volume and surface area increased under OHT, which was exaggerated
under NAM treatment (n = 9729 disconnected volumes in NT, 8026 in OHT, 6413 in OHT-NAM). Zoom = inset of data points. Scale bar in A = 5 μm ***P < 0.001.

supplementation was unable to prevent these morphological changes
even though NAM treatment was grossly neuroprotective (Fig. 9C and
D). These data suggest that even across a range of insults, mitochondria
increase or maintain their size when NAM is present. However, these
changes may reflect the tissue culture conditions (e.g. Ca2+ buffering
deficits or deviation from normoxia in the axotomy model) or the abrupt
complete physiological loss of mitochondrial Complex I function (in the
rotenone model) which are exaggerations of the intrinsic RGC injury
responses during glaucoma pathogenesis.
In order to differentiate NAM-induced and insult-induced mito
chondrial changes we administered NAM in the diet of uninjured control
MitoV mice for 1 week prior to fixation and imaging (Fig. 9E). RGC
mitochondria in the GCL/RNFL increased in volume and surface area
compared to untreated controls, suggesting that the increase in volume
and surface area observed in the NAM treated injury paradigms were
NAM specific responses (Fig. 9F). The presence of larger mitochondria
prior to damage may therefore explain the maintenance of mitochon
drial volume and surface area which was observed in the rat GCL/RNFL
in NAM treated injuries and the exaggerated mitochondrial expansion
seen in the rat IPL. In vivo imaging of MitoTracker labelled mitochondria
in purified cultured RGCs (Fig. 10A) demonstrated an increase in
mitochondrial size following NAM supplementation (24 h of pretreatment) which was dose dependent (Fig. 10B). Mitochondria occu
pied a greater proportion of neurite length (Fig. 10B). Live imaging,
analyzed as kymographs (Fig. 10C), revealed a greater number of
mitochondria and a striking increase in mitochondrial population
mobility and velocity across NAM doses over untreated control
(Fig. 10D). Total and stationary mitochondria displayed some variability
with NAM dose (Fig. 10D). Larger, more mobile mitochondria may be
indicative of increased mitochondrial fusion, with implications for
increased OXPHOS capacity (as supported by the increased oxygen
consumption rate) and maintenance of energy demands across the cell.

3.6. Nicotinamide reduces retinal ganglion cell metabolic demands
Since OXPHOS capacity and mitochondrial motility increased
following NAM application, we questioned whether RGC electrical ac
tivity was altered. Mouse retina were explanted and incubated with
NAM for 2 h before patch clamping (example profiles displayed in
Fig. 11A). At low NAM doses (1–10 mM) the action potential (AP) firing
rate was slightly increased, with persistent firing at higher current in
puts. Higher NAM doses (100–250 mM), in which we demonstrated
neuroprotection in explant retina, demonstrated marked reduction in AP
firing rates across current inputs (Fig. 11B). The firing rate (I/O rela
tionship AUC), AP amplitude, and AP rise time were significantly
reduced at higher NAM doses (Fig. 11C). Resting membrane potential,
AP threshold, and rheobase were not affected by NAM suggesting
integrity of the cell’s capacity to depolarize (Fig. 11D). These data
suggest that the higher neuroprotective doses of NAM lower AP firing
frequency in RGCs, without compromising their potential to fire, and
thus may reduce RGC metabolic demands. Post-hoc morphological
analysis of filled cells confirmed that all recorded cells were RGCs
(presence of an axon). RGCs demonstrated broadly similar morphologies
between conditions but with some variability (Supplementary Fig. 6).
No cells were bi-stratified, and no cells had offset dendritic fields. This
suggests that the observed changes to AP metrics are not predominantly
the result of differing RGC types. RGCs within the group treated with 1
mM NAM had significantly larger dendritic fields and somas compared
to untreated RGCs (control) and as such may contain a different pro
portion of RGC subtypes which could account for the observed differ
ence in AP metrics in this group.
4. Discussion
The control of metabolic homeostasis is essential for normal physi
ology as well as during stress- and disease-related episodes. To assess
this in the context of ocular disease, we introduce a novel, small
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Fig. 9. Nicotinamide increases mitochondrial size. (A) Retinal axotomy culture of MitoV mice (RGC specific YFP labelled mitochondria in the inner retina)
maintained for 0.5 days ex vivo (DEV) with or without NAM treated media (and controls fixed at point of euthanasia, 0 DEV) allowed imaging of RGC specific
mitochondria in the GFL/RNFL by Airy confocal scanning microscopy following flat mounting (n = 4 retina for all conditions). (B) The mean mitochondrial volume
and surface area were increased under axotomy, with a further increase in size under NAM treatment (n = 15,216 disconnected volumes in 0 DEV, 16,765 in 0.5 DEV,
24,558 in 0.5 DEV + NAM). (C) The effects NAM at mitigating direct mitochondrial stress were investigated by intravitreal rotenone injection in MitoV mice (n = 9
DMSO vehicle treated retina, 3 rotenone, 7 rotenone + NAM (500 mg/kg/d)). Tissue was cryo-sectioned and imaged by Airy confocal scanning microscopy and
mitochondria within the IPL (boundary demarcated by cyan broken line). (D) Rotenone caused a reduction in mitochondrial volume relative to controls (DMSO
vehicle) in the IPL. NAM had little effect is preventing this change (n = 15,380 disconnected volumes in DMSO vehicle treated retinas, 7987 in rotenone treated,
10,418 in rotenone + NAM). These results demonstrate the heterogeneous nature of OHT insult on mitochondria that shares features with both direct RGC and direct
mitochondrial stress. (E) In order to determine whether NAM increases mitochondrial size in uninjured retina, MitoV mice were maintained on a NAM diet (500 mg/
kg/d) for 1 week. Retina were fixed immediately after euthanasia and compared to untreated controls by Airy confocal imaging and reconstruction (n = 4 control
retinas, 4 NAM supplemented). (F) NAM supplementation increased mean mitochondrial volume and surface area in RGCs, supporting observations of mitochondria
under stress above (n = 15,216 disconnected volumes in control, 13,306 in NAM supplemented). Zoom = inset of data points. Scale bar = 5 μm in A, C, and E. **P <
0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 10. Nicotinamide increases mitochondrial motility in RGCs. (A) In order to observe these NAM effects on mitochondria in vivo, RGC cultures were grown
and exposed to NAM treated media for 24 h. MitoTracker labelled mitochondria were time-lapse imaged over 10 min (example images shown in A and as kymographs
in C where the y axis = time (t) and the x axis = distance long the neurite (d)). Morphology was examined in the first frame and demonstrated that mitochondrial
length was increased with increasing NAM concentration (B; n = 148 mitochondria in control, 154 in 50 μM NAM, 141 in 100 μM NAM, 140 in 500 μM NAM, 122 in
1000 μM NAM; mitochondria from 8 neurites from 3 independent cultures for all conditions). Mitochondria occupied a greater percentage of neurite length in NAM
exposed retina (B; n = 8 neurites from 3 independent cultures for all conditions), which was partially explained by an increase in observed mitochondria (D). Analysis
of mitochondrial movements demonstrated a greater number of both mobile and stationary mitochondria (D; n = 3 independent cultures for all conditions).
Mitochondrial velocity was significantly increased with NAM supplementation (D; n = 52 mitochondria in control, 356 in 50 μM NAM, 324 in 100 μM NAM, 249 in
500 μM NAM, 292 in 1000 μM NAM; mitochondria from 3 independent cultures for all conditions). Since a greater number of stationary mitochondria were observed,
this suggests that the increase in mitochondria numbers may be a factor of increase mitochondrial biogenesis. Scale bar = 10 μm in A and 20 μm in C. *P < 0.05, **P
< 0.01, ***P < 0.001.

molecular weight metabolome for the retina, optic nerve, and superior
colliculus of the Brown Norway rat (Rattus norwegicus; the genetic
standard for rat). We demonstrate that ocular hypertension causes early
metabolic dysregulation that is largely prevented by nicotinamide
treatment. These data advance the understanding of nicotinamide as a
treatment for glaucoma by demonstrating substantial metabolic pro
tection and robust mitigation of glaucoma-related insults across multiple
retinal ganglion cell compartments. Elevated IOP is a major risk factor
for glaucoma and is the most significant factor in many patients. We
modelled glaucoma in this context with an acute, inducible IOP increase
(ocular hypertension) and demonstrate that retinal and optic nerve NAD
decline following ocular hypertension in the absence of an age-related
effect on NAD homeostasis. It is important to note that significant
retinal ganglion cell death has occurred at this time point (which may
influence whole tissue NAD metabolism) and that at an earlier 3 day
time point (high IOP, but no detectable retinal ganglion cell death [11])
NAD is yet to decline. In order to better understand the temporal nature
of NAD decline and its role in glaucoma pathophysiology it will be
important to investigate further disease time points to identify whether
ocular hypertension related NAD decline precedes retinal ganglion cell
death. Metabolomics revealed a number of significantly altered metab
olites in the retina and superior colliculus, but with no detectable

changes in the optic nerve at this early 3 day time point. Ocular hy
pertension does not directly insult the superior colliculus. Therefore, any
metabolic disruption to the superior colliculus must arise from retinal
ganglion cell mediated processes, not limited to metabolic stress, but
could include stresses such as loss of axoplasmic transport [11,34]. We
cannot discount early neurodegenerative changes in the optic nerve on
the basis of the absence of metabolic dysfunction (as detected using this
metabolomics panel). However, the nicotinamide induced metabolic
changes observed in normal optic nerve were lost in nicotinamide
treated ocular hypertension optic nerves, which may imply subtle optic
nerve metabolic changes during ocular hypertension. Crucially, NAD,
NADH, and nicotinamide were all significantly elevated in ocular hy
pertensive nicotinamide treated optic nerves. As NAD is crucial for axon
protection [33], this suggests the potential for long term neuro
protection of the optic nerve in glaucoma.
Our previous experiments using the DBA/2J mouse demonstrated
that increasing NAD via Nmnat1 gene therapy provides a robust neu
roprotection. Over-expression of Nmnat1 provides this neuroprotection
outside of the context of increased nicotinamide, but is additive when
additional nicotinamide is added to the system [5]. It is therefore
reasonable to hypothesize that directly increasing NAD provides retinal
ganglion cell neuroprotection in this context, which is supported by the
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Fig. 11. Nicotinamide lowers action potential firing frequency in RGCs. (A) Mouse retina were explanted and incubated with NAM for 2hrs before patch
clamping. Example traces for individual RGCs are shown for each treatment group (0 mV profile in grey, 50 mV profile in color, 100 mV profile in grey; total RGCs =
twelve control, eleven 1 mM NAM, ten 10 mM NAM, 17,100 mM NAM, eleven 250 mM NAM, from 3 retinas for each condition). (B) Action potential (AP) firing
frequency was markedly reduced at higher doses of NAM (analogous to those that provide neuroprotection in the axotomy explant model). (C) The relationship of
input current to output demonstrates a slight increase in AP firing at high current for low dose NAM (1 and 10 mM) with a significant reduction in firing across a large
range of input currents for higher doses (100 and 250 mM). (C) AP amplitude was significantly reduced at the higher doses and AP rise-time was significantly
increased. (D) NAM did not affect the resting membrane potential, threshold for achieving an AP or the Rheobase indicating that the potential/ability to fire was not
altered. Reducing AP firing may lower the metabolic demands of RGCs thus contributing to its neuroprotective effects. *P < 0.05, **P < 0.01, ***P < 0.001. (For
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

role of NAD in Wallerian degeneration [35]. However, there are other
potential metabolic processes afforded by increasing nicotinamide levels
that may confer, or partially confer, neuroprotection in addition to
nicotinamide’s role in elevating NAD. In the nicotinamide treated tissue
we cannot differentiate whether these metabolic changes are a conse
quence of neuroprotection itself or are directly providing neuro
protection. Following ocular hypertension, we observed a number of
changed metabolites that may influence retinal ganglion cell neuro
degeneration and neuroprotection. Creatine and creatinine were altered
in the retina following ocular hypertension. Supporting this, creatine
kinase (responsible for the conversion of creatine to phosphocreatine)
expression is altered in retinal ganglion cells in the DBA/2J mouse
model of glaucoma in response to elevated IOP. Ckb (creatine kinase,
brain; coupled to glycolysis) is up-regulated and Ckmt1 (creatine kinase,
mitochondrial 1; coupled to OXPHOS) is down-regulated [5]. The cre
atine/phosphocreatine/creatine kinase system provides an important
ATP buffer and energy shuttle system within tissues with high energy
demand and fluctuation (since phosphocreatine cycling back to creatine
generates ATP) [36]. Creatine supplementation is neuroprotective to
retinal ganglion cells in cell culture but not in other in vivo in models of
retinal excitotoxicity or acute ischemic injury [37]. We observed an
increase in α-ketoglutaric acid, a key TCA cycle intermediate. α-keto
glutarate dehydrogenase catalyzes the conversion of α-ketoglutarate to
succinyl CoA (an NAD dependent reaction [38]). Reduction in the ac
tivity of α-ketoglutarate dehydrogenase is well-established in many

neurodegenerative diseases with a metabolic component [39]. We
observed increased homocysteine in the retina following ocular hyper
tension, which suggests potential neurotoxic metabolic changes in
addition to energy disruption. Increased homocysteine has been
described as a marker of a number of neurodegenerative diseases [40]
and has been demonstrated to induce retinal ganglion cell death in vitro
and in vivo (likely through an excitotoxicity mechanism) [41,42].
Further to this, glycerophosphocholine was also increased in ocular
hypertension. Increased glycerophosphocholine is established as an in
dicator of membrane integrity disruption in neurodegenerative disease
[43] created by the breakdown of phosphatidylcholine by phospholi
pase A2. Phospholipase A2 inhibitors or genetic knockout of phospholi
pase A2 reduce ischemic neurodegeneration and attenuates Alzheimer’s
disease in mouse models [44,45]. Supporting this, phospholipase A2
activation has also been demonstrated in Alzheimer’s disease patients
and post-mortem tissue [46,47]. Taken together, the neuroprotective
role of nicotinamide may not be solely limited to its capacity to generate
NAD, however these additional metabolites need to be definitively
mechanistically tested.
Nicotinamide treatment robustly protected against retinal ganglion
cell damaging events. The maintenance of cellular NAD pools is critical
for neuronal survival as it provides co-enzyme resources necessary for
maintaining a variety of complex cellular functions including ATP pro
duction, protein deacetylase activity, calcium homeostasis, conversion
to NADPH, and the maintenance of gene expression and DNA repair [33,
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48]. The presence of metabolic dysregulation and ATP depletion [5,49],
calcium dysregulation [50], mitochondrial degeneration [4,5], and
reactive oxygen species [51] all contribute to glaucoma pathogenesis,
supporting a role for NAD as a critical regulator of neuronal health in
glaucoma. Nicotinamide supplementation is, therefore, likely to confer
multiple neuroprotective effects. These features are not unique to
glaucoma and are common to other neurodegenerative diseases in
which mitochondrial degeneration and metabolic dysfunction occur.
Increasing NAD through multiple substrate avenues has protective ef
fects in many of these diseases, including Alzheimer’s disease [52–55],
Parkinson’s disease [56–59], other neurodegenerations [60,61], and
other mitochondrial degenerative disorders [62,63]. Continued eluci
dation of the mechanisms of Wallerian degeneration has further
demonstrated the role of NAD in axon survival. NAD decreases in
damaged axons [64], while expression of the WldS allele or viral over
expression/modified localization of NMNATs are protective, restoring
NAD levels [5,65–68]. Increased NAD appears to exhibit numerous
functional local roles in this context, including providing sufficient
substrate to mitigate local SARM1-dependent NAD consumption and
protecting against nicotinamide mononucleotide (NMN) induced axon
damage [69,70].
Metabolomic analysis confirmed that retina, optic nerve, and supe
rior colliculus all demonstrated increased NAD following nicotinamide
administration. Importantly, nicotinamide drove an increase in NAD in
mature in vivo systems and in isolated neurons demonstrating that
retinal neurons themselves are capable of utilizing nicotinamide without
a requirement for first-pass metabolism or other structural chemical
changes. Crucially, high dose nicotinamide caused minor changes to the
normal metabolome, mostly influencing metabolites linked directly to
NAD or increasing amino acids L-threonine, L-glutamate, L-aspartate, and
phenylalanine with limited predicted pathway effects (i.e. low predicted
impact on critical pathway nodes via KEGG analysis), suggesting that
chronic nicotinamide treatment is unlikely to have substantial delete
rious effects in visual system tissue metabolism in the long-term. This is
important if nicotinamide is to be considered as a prophylactic in
glaucoma patients where significant neurodegeneration is yet to occur.
Hierarchical clustering revealed that tissues could be grouped based on
the presence or absence of nicotinamide treatment over disease related
changes. However, this was largely driven by large fold changes in a
small number of metabolites in nicotinamide treatment as opposed to
smaller fold changes in numerous metabolites in ocular hypertension.
Metabolic stabilization and neuroprotection were achieved with rela
tively short-term administration of nicotinamide (1 week prophylactic),
and dissociated neurons were capable of mobilizing nicotinamide to
NAD rapidly (within hours), demonstrating the short period required to
achieve an increase in cellular NAD pools. These results support nico
tinamide supplementation as a therapeutic strategy for neuroprotection
in glaucoma with particular regard to its rapid mobilization to NAD in
visual system tissues. While the rodent and human visual system share
many common features, and NAD synthesis pathways are conserved, the
metabolic consequences in humans could vary. As we focused on small
molecular weight metabolites, the consequences to the whole metab
olome remain unknown and further metabolomics and lipidomic studies
in humans will be necessary especially within the context of clinical
trials and long-term testing. To our knowledge, this is the first small
molecular weight metabolome for these tissues which will provide a
resource and may aid others in the identification of key metabolic
changes related to visual pathologies.
The extent to which the NAD increases were restricted to retinal
ganglion cells is not known since the metabolomics data is derived from
a mixed cell population which included retinal ganglion cell compart
ments. The optic nerve, containing retinal ganglion cell axons, repre
sents the most retinal ganglion cell enriched tissue based on the relative
abundance of cell types, suggesting that retinal ganglion cells likely
exhibit increased NAD following nicotinamide supplementation.
Increasing NAD across multiple cell types, including glia which offer

metabolic support to retinal ganglion cells, may enhance the neuro
protective effect, yet this remains to be explored and is an exciting
avenue for therapeutic research, especially in other neurodegenerative
diseases in which compromised metabolic function is coupled with a
neuroinflammatory components such as Alzheimer’s disease. Increasing
NAD production by Nmnat1 gene therapy in retinal ganglion cells is
neuroprotective and supports a hypothesis in which retinal ganglion cell
specific strategies to increase NAD are neuroprotective [5]. Since the
intracellular location of NAD is key to its neuroprotective effects [71]
further studies examining this in retinal ganglion cells will aid in
elucidating the mechanisms of neuroprotection.
We identify mitochondrial protection and oxidative phosphorylation
maintenance as potential routes to buffering retinal ganglion cells bio
energetic insufficiency [72–74]. Nicotinamide treatment increased
mitochondrial size in normal and disease conditions (ocular hyperten
sion and axotomy, but not rotenone which specifically insults mito
chondria). However, differing mitochondrial populations may reflect
the health of the neuron rather than a direct nicotinamide effect on
mitochondrial morphology. In cultured retinal ganglion cells, nicotin
amide also increased basal mitochondrial size. Basal mitochondrial
mobility was also significantly increased by nicotinamide. Typically,
mitochondrial biogenesis occurs at the soma and anterograde axonal
transport moves these new mitochondria down the axon, whereas
retrograde axonal transport returns dysfunctional mitochondria to the
soma for degradation [75]. Mitochondrial transport is ATP dependent
and our data suggest a greater free ATP pool following nicotinamide
administration. NAD levels are known to play an important regulatory
role in mitochondrial biogenesis and degradation (in particular through
SIRT1 and SIRT3 activity, which is increased by NAD [76–78]). Sup
porting this, DBA/2J mice administered nicotinamide demonstrate an
increase in Ppargc1 expression in retinal ganglion cells (encodes PGC-1α;
a master regulator of mitochondrial biogenesis) [5].
Electrophysiological analysis of retinal ganglion cells demonstrated
that nicotinamide treatment lowered action potential firing rates at the
doses associated with neuroprotection. Further experiments will be
necessary to corroborate these findings since we only sampled small
numbers of retinal ganglion cells. Nicotinamide may elicit differing re
sponses among the different retinal ganglion cell subtypes and using
subtype reporter strains would allow isolation of specific subtypes of
retinal ganglion cells. Alternatively, the use of multi-electrode arrays
would facilitate the capture of hundreds of retinal ganglion cell re
sponses which would deliver sufficient numbers so as to produce pop
ulations with similar subtype compositions between comparisons. By
washing in/out nicotinamide, the same cell could be followed over time,
which would inform on the longevity and/or reversibility of the firing
suppression. It should be noted that all of these methods are caveated as
the preparation requires an axotomized retina. However, in other tissue
preparations exogenous nicotinamide and NAD have demonstrated
similar suppression and prolongation of action potential firing and ac
tivity (neuronal and cardiac preparations) [79–83]. It is important to
note that nicotinamide has been used therapeutically at high doses
long-term in clinical preparations without noted incidences of visual or
cognitive disturbances [9,74]. Pattern electroretinogram (ERG) is a
retinal ganglion cell specific functional test, representing a global
summation of retinal ganglion cell signals. Nicotinamide supplementa
tion was sufficient to preserve pattern ERG under chronic glaucomatous
pathology [5,84] and has demonstrated a recovery in visual function as
assessed by ERG in human glaucoma patients [7]. These findings suggest
that even if the changes in retinal ganglion cell activity identified by
patch clamping were recapitulated in vivo, visual function would not be
disturbed. A concomitant decrease in retinal ganglion cell metabolic
demand through reduced action potential firing frequency could miti
gate the effects of a retinal ganglion cell energy crisis. A reduced ener
getic load on retinal ganglion cells may partially explain enhanced
survival.
These findings advocate furthering clinical trials for the use of
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nicotinamide as a treatment for glaucoma. Nicotinamide has a long
established clinical safety profile, with limited long-term side effects.
Long-term clinical trials that include individuals with early glaucoma (in
which cell loss is heterogeneous and a significant portion of healthy cells
likely remain) will be essential in determining the potential for nico
tinamide as a prophylactic treatment for glaucoma. However, longerterm treatment of nicotinamide in animals retain their importance,
especially in non-human primates which closely recapitulate the human
visual system. A number of disease preventative measures have been
identified in animal models of glaucoma, which provide robust treat
ment at early and mid-disease time points, but long-term neuro
protective effects are not maintained or are yet to be demonstrated [18,
85–88]. Animals were treated with high doses of nicotinamide that
represent achievable scaled doses to humans (the lowest neuro
protective dose here of 200 mg/kg/d in the rat representing 1.9 g/day in
a 60 kg human [31]). While we did not test any extra-visual system
effects of these doses, the safety of the doses suggested here, as well as
doses up to 12 g/d, is already established [9]. Although some patients
may find adherence to these doses difficult to achieve because of the
necessary number of tablets (especially when taken in addition to other
common medications typical of more elderly patients) and the regularity
of dosing, doses in the 1–3 g/d range are likely to be suitable for many
patients. Supporting this, 3 g/d (6 × 500 mg capsules) had a high
tolerance and compliance in Hui et al. nicotinamide glaucoma clinical
trial (94% adherence).
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5. Conclusions
Collectively, our data suggest that nicotinamide given as an early
intervention or as a prophylactic treatment produces minimal shortterm changes to healthy, non-disease visual system tissue with no
observed deleterious effects to normal retinal ganglion cells. Nicotin
amide buffers against metabolic and bioenergetic insufficiency to pro
vide a potent neuroprotection against a variety of glaucoma-related
stresses. The doses used here are realistic for human treatment regimens
and support further clinical trials for glaucoma as well as potentially a
range of metabolic and ophthalmic diseases.
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[59] D.C. Schöndorf, D. Ivanyuk, P. Baden, A. Sanchez-Martinez, S. De Cicco, C. Yu, et
al., The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and
neuronal loss in iPSC and fly models of Parkinson’s disease, Cell Rep. 23 (10)
(2018) 2976–2988.
[60] J.B. Lin, S. Kubota, N. Ban, M. Yoshida, A. Santeford, A. Sene, et al., NAMPTmediated NAD(+) biosynthesis is essential for vision in mice, Cell Rep. 17 (1)
(2016) 69–85.
[61] H.W. Liu, C.B. Smith, M.S. Schmidt, X.A. Cambronne, M.S. Cohen, M.E. Migaud, et
al., Pharmacological bypass of NAD + salvage pathway protects neurons from
chemotherapy-induced degeneration, Proc. Natl. Acad. Sci. U. S. A. 115 (42)
(2018) 10654–10659, https://doi.org/10.1073/pnas.1809392115.
[62] N.A. Khan, M. Auranen, I. Paetau, E. Pirinen, L. Euro, S. Forsström, et al., Effective
treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3,
EMBO Mol. Med. 6 (6) (2014) 721–731.
[63] E. Pirinen, M. Auranen, N.A. Khan, V. Brilhante, N. Urho, A. Pessia, et al., Niacin
Cures Systemic NAD + Deficiency and Improves Muscle Performance in AdultOnset Mitochondrial Myopathy, Cell Metabol. 31 (6) (2020) 1078–1090, https://
doi.org/10.1016/j.cmet.2020.04.008, e5.
[64] J. Wang, Q. Zhai, Y. Chen, E. Lin, W. Gu, M.W. McBurney, et al., A local mechanism
mediates NAD-dependent protection of axon degeneration, J. Cell Biol. 170 (3)
(2005) 349–355.
[65] T. Araki, Y. Sasaki, J. Milbrandt, Increased nuclear NAD biosynthesis and SIRT1
activation prevent axonal degeneration, Science 305 (5686) (2004) 1010–1013.
[66] E. Babetto, B. Beirowski, L. Janeckova, R. Brown, J. Gilley, D. Thomson, et al.,
Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency
in vivo, J. Neurosci. 30 (40) (2010) 13291–13304.
[67] Y. Feng, T. Yan, J. Zheng, X. Ge, Y. Mu, Y. Zhang, et al., Overexpression of Wld(S)
or Nmnat2 in mauthner cells by single-cell electroporation delays axon
degeneration in live zebrafish, J. Neurosci. Res. 88 (15) (2010) 3319–3327.
[68] P.A. Williams, J.M. Harder, N.E. Foxworth, B.H. Cardozo, K.E. Cochran, S.W.
M. John, Nicotinamide and WLDS act together to prevent neurodegeneration in
glaucoma, Front. Neurosci. 11 (2017).

[69] M. Di Stefano, I. Nascimento-Ferreira, G. Orsomando, V. Mori, J. Gilley, R. Brown,
et al., A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury
promotes axon degeneration, Cell Death Differ. 22 (5) (2015) 731–742.
[70] J. Gerdts, E.J. Brace, Y. Sasaki, A. DiAntonio, J. Milbrandt, SARM1 activation
triggers axon degeneration locally via NAD⁺ destruction, Science 348 (6233)
(2015) 453–457.
[71] J. Gilley, M.P. Coleman, Endogenous Nmnat2 is an essential survival factor for
maintenance of healthy axons, PLoS Biol. 8 (1) (2010), e1000300.
[72] L.E. Fry, E. Fahy, V. Chrysostomou, F. Hui, J. Tang, P. van Wijngaarden, et al., The
coma in glaucoma: retinal ganglion cell dysfunction and recovery, Prog. Retin. Eye
Res. 65 (2018) 77–92.
[73] R.J. Casson, G. Chidlow, J.G. Crowston, P.A. Williams, J.P.M. Wood, Retinal
energy metabolism in health and glaucoma, Prog. Retin. Eye Res. (2020) 100881.
[74] P.A. Williams, J.M. Harder, S.W.M. John, Glaucoma as a metabolic optic
neuropathy: making the case for nicotinamide treatment in glaucoma, J. Glaucoma
26 (12) (2017) 1161–1168.
[75] H. Chen, D.C. Chan, Mitochondrial dynamics–fusion, fission, movement, and
mitophagy–in neurodegenerative diseases, Hum. Mol. Genet. 18 (R2) (2009)
R169–R176.
[76] J. Milner, Cellular regulation of SIRT1, Curr. Pharmaceut. Des. 15 (1) (2009)
39–44.
[77] J. Brenmoehl, A. Hoeflich, Dual control of mitochondrial biogenesis by sirtuin 1
and sirtuin 3, Mitochondrion 13 (6) (2013) 755–761.
[78] A. Benigni, L. Perico, D. Macconi, Mitochondrial dynamics is linked to longevity
and protects from end-organ injury: the emerging role of sirtuin 3, Antioxidants
Redox Signal. 25 (4) (2016) 185–199.
[79] M. Liang, X.L. Yin, L.Y. Wang, W.H. Yin, N.Y. Song, H.B. Shi, et al., NAD+
attenuates bilirubin-induced hyperexcitation in the ventral cochlear nucleus by
inhibiting excitatory neurotransmission and neuronal excitability, Front. Cell.
Neurosci. 11 (2017) 21.
[80] J.M. Bold, C.R. Gardner, R.J. Walker, Central effects of nicotinamide and inosine
which are not mediated through benzodiazepine receptors, Br. J. Pharmacol. 84 (3)
(1985) 689–696.
[81] K.B. Pustovit, D.V. Abramochkin, Effects of nicotinamide adenine dinucleotide
(NAD(+)) and diadenosine tetraphosphate (Ap4A) on electrical activity of working
and pacemaker atrial myocardium in Guinea pigs, Bull. Exp. Biol. Med. 160 (6)
(2016) 733–736.
[82] V.S. Kuzmin, K.B. Pustovit, D.V. Abramochkin, Effects of exogenous nicotinamide
adenine dinucleotide (NAD+) in the rat heart are mediated by P2 purine receptors,
J. Biomed. Sci. 23 (1) (2016) 50.
[83] K.B. Pustovit, V.M. Potekhina, A.D. Ivanova, A.M. Petrov, D.V. Abramochkin, V.
S. Kuzmin, Extracellular ATP and β-NAD alter electrical properties and cholinergic
effects in the rat heart in age-specific manner, Purinergic Signal. 15 (1) (2019)
107–117.
[84] T.H. Chou, G.L. Romano, R. Amato, V. Porciatti, Nicotinamide-rich diet in DBA/2J
mice preserves retinal ganglion cell metabolic function as assessed by PERG
adaptation to flicker, Nutrients 12 (7) (2020).
[85] G.R. Howell, I. Soto, X. Zhu, M. Ryan, D.G. Macalinao, G.L. Sousa, et al., Radiation
treatment inhibits monocyte entry into the optic nerve head and prevents neuronal
damage in a mouse model of glaucoma, J. Clin. Invest. 122 (4) (2012) 1246–1261.
[86] A.J. Weber, C.D. Harman, BDNF preserves the dendritic morphology of alpha and
beta ganglion cells in the cat retina after optic nerve injury, Invest. Ophthalmol.
Vis. Sci. 49 (6) (2008) 2456–2463.
[87] J. Agostinone, L. Alarcon-Martinez, C. Gamlin, W.Q. Yu, R.O.L. Wong, A. Di Polo,
Insulin signalling promotes dendrite and synapse regeneration and restores circuit
function after axonal injury, Brain 141 (7) (2018) 1963–1980.
[88] R.H. Foxton, A. Finkelstein, S. Vijay, A. Dahlmann-Noor, P.T. Khaw, J.E. Morgan,
et al., VEGF-A is necessary and sufficient for retinal neuroprotection in models of
experimental glaucoma, Am. J. Pathol. 182 (4) (2013) 1379–1390.

21

